Team:Paris Bettencourt/Results

From 2013.igem.org

(Difference between revisions)
Line 139: Line 139:
     </div>
     </div>
     <div class="bkgr" style="width:315px;">
     <div class="bkgr" style="width:315px;">
-
       <h2>TB facts</h2>
+
       <h2><h2><a href="https://2013.igem.org/Team:Paris_Bettencourt/Human_Practice/TB_Gallery"> TB gallery</h2>
-
       <p> Infographics page containing TB data and facts that captures all you need to know at a glance.</p>
+
       <p> A gallery of famous historic figures who had tuberculosis, from Antiquity to the 20th century, made to raise awareness to the prevalence in the psat and present .</p>
     </div>
     </div>
 +
 +
     <div class="bkgr" style="width:315px;margin-bottom:0">
     <div class="bkgr" style="width:315px;margin-bottom:0">
-
       <h2>TB facts</h2>
+
       <h2><a href="https://2013.igem.org/Team:Paris_Bettencourt/Human_Practice/TB_France">TB facts</h2>
       <p> Infographics page containing TB data and facts that captures all you need to know at a glance.</p>
       <p> Infographics page containing TB data and facts that captures all you need to know at a glance.</p>
     </div>
     </div>

Revision as of 02:24, 5 October 2013

Detect

Background

CRISPR/Cas systems generate site-specific double strand breaks and have recently be used for genome editing.

Results

  • Successfully cloned gRNA anti-KAN, crRNA anti-KAN, tracrRNA-Cas9 and pRecA-LacZ into Biobrick backbones and therefore generated four new BioBricks.
  • Testing the new assembly standard for our cloning.

Aims

Building a genotype sensor based on CRISPR/Cas that reports existance of an antibiotic resistance gene.

Target

Background

SirA is an essential gene in latent tuberculosis infections

Results

  • Produced an E. coli strain which relies upon mycobacterial sirA, fprA and fdxA genes to survive in M9 minimal media
  • Demonstrated that E. coli can survive with mycobacterial sulfite reduction pathway with Flux Balance Analysis
  • Located drug target sites on sirA as well as identified high structural similarity between cysI and sirA through structural anaylsis

Aims

To perform an drug screen targeted at the sirA gene from mycobacteria

Infiltrate

Background

Latent tuberculosis persists inside macrophages of the lungs, where it is partially protected from both the host immune system and conventional antibiotics.

Results

  • We expressed the enzyme Trehalose Dimycolate Hydrolase (TDMH) in E.coli and showed that it is highly toxic to mycobacteria in culture.
  • We expressed the lysteriolyin O (LLO) gene in E. coli and showed that it is capable of entering the macrophage cytosol.
  • We co-infected macrophages with both mycobacteria and our engineered E. coli to characterize the resulting phagocytosis and killing.

Aim

To create an E. coli strain capable of entering the macrophage cytosol and delivering a lytic enzyme to kill mycobacteria.

Sabotage

Background

One of the main concern about tuberculosis today is the emergence of antibiotic resistant strain

Results

  • Construction and characterization of phagemids coding for small RNA targeting antibiotic resistance proteins
  • successful conversion of antibiotic resistant population of E. coli to a sensitive state

Aims

Our objective is to make an antibiotic-resistant bacterial population sensitive again to those same antibiotics.

Human Practice

TB facts

Infographics page containing TB data and facts that captures all you need to know at a glance.

Gender Study

    A comprehensive and quantitative study of gender equality(equality) in iGEM and synthetic biology. A database was gathered to depict sex ratio in teams' students and supervisors in all iGEM teams as well as other available information. This was statistically analysed to investigate gender in(equality) in iGEM, as well as SB conferences and synthetic biology labs.

TB Galle

Centre for Research and Interdisciplinarity (CRI)
Faculty of Medicine Cochin Port-Royal, South wing, 2nd floor
Paris Descartes University
24, rue du Faubourg Saint Jacques
75014 Paris, France
+33 1 44 41 25 22/25
team2013@igem-paris.org
Hit Counter by Digits
Copyright (c) 2013 igem.org. All rights reserved.